Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 8;17:4059–4071. doi: 10.2147/IJN.S380598

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Zou et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Recombinant HDL promoted cellular uptake of HDL nanoparticles by OCCs and S-HDL exerted stronger cytotoxicity than unencapsulated Sal in OCCs and OCSCs. (A) Expression of LRP-1 in OCCs, OCSCs and IOSE80. (B) Cellullar uptake of HDL nanoparticles (confocal laser microscope, scale bar = 50μm) (, n=3) (**P < 0.01, compared with IOSE80 cells). (C) The IC50 of S-HDL on OCCs and OCSCs for 48h treatment. (D) Cell viability of OCCs and OCSCs after being treated with different concentrations of S-HDL and Sal for 48h (, n=3) (*P < 0.05, **P < 0.01, ***P < 0.001, *compared with PBS treatment group; ^#P < 0.05, ^##P < 0.01, ^#compared with Sal treatment group).

Inline graphic — Recombinant HDL promoted cellular uptake of HDL nanoparticles by OCCs and S-HDL exerted stronger cytotoxicity than unencapsulated Sal in OCCs and OCSCs. (A) Expression of LRP-1 in OCCs, OCSCs and IOSE80. (B) Cellullar uptake of HDL nanoparticles (confocal laser microscope, scale bar = 50μm) (, n=3) (**P < 0.01, compared with IOSE80 cells). (C) The IC50 of S-HDL on OCCs and OCSCs for 48h treatment. (D) Cell viability of OCCs and OCSCs after being treated with different concentrations of S-HDL and Sal for 48h (, n=3) (*P < 0.05, **P < 0.01, ***P < 0.001, *compared with PBS treatment group; ^#P < 0.05, ^##P < 0.01, ^#compared with Sal treatment group).